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AbstrACt
Aim The aim of this study was to assess the cost 
effectiveness of the Pill Protect (PP) genetic screening 
test for venous thromboembolism (VTE) risk compared 
with standard of care (SoC), for women considering 
combined hormonal contraceptives (CHCs) in 
Switzerland.
Methods A two- part microsimulation model was 
developed to estimate VTE events, costs and quality- 
adjusted life years (QALYs) associated with the PP and 
SoC strategies. In the first portion of the model, a cohort 
of 1 million Swiss first- time seekers of a CHC were 
simulated. It was determined whether each women 
would receive a CHC or non- CHC by using prescribing 
patterns elicited from a modified Delphi study. These 
results formed the basis of the SoC strategy. For the 
PP strategy, a PP test was included and the results 
considered in addition to SoC practice. Each woman 
then entered a Markov model that captured morbidity 
and mortality over a lifetime. The risk of having a VTE 
was derived from the risk algorithm that underpins 
the PP test. The remaining model inputs relating to 
population characteristics, costs, health resource use, 
mortality and utilities were derived from published 
studies or national sources. The model was validated 
and calibrated to align with population- based studies. 
Extensive uncertainty analyses were conducted.
results From a Swiss health system perspective, the PP 
strategy in comparison with the SoC strategy generated an 
additional CHF 231, and gained 0.003 QALYs per woman, 
leading to an incremental cost- effectiveness ratio of CHF 
76 610 per QALY gained. Assuming a threshold of CHF 100 
000 per QALY gained, the PP strategy is likely to be cost 
effective. Our results were generally robust to variations in 
the parameter values.
Conclusions The PP test may be cost effective in 
Switzerland for screening women seeking CHCs for their 
risk of VTE based on the current evidence.
IntroduCtIon
The development of the contraceptive 
‘pill‘ began in the 20th century and gained 
popularity due to its benefits in controlling 
menstrual bleeding and as a simple and 
effective family planning mechanism.1 2 The 
combination of ethinyl estradiol (EE) and 
various progestins has become the basis for 
combined (hormonal) oral contraceptives. 
Combined hormonal contraceptives (CHCs) 
comprise oral pills and other contraceptive 
devices (ie, rings or patches) that contain 
oestrogen in combination with a progestogen.
Venous thrombosis is a serious medical 
condition that occurs when a blood clot 
strengths and limitations of this study
 ► We used advanced quantitative methods to appro-
priately model the long- term costs and effects of the 
strategies compared.
 ► In addition, we undertook primary qualitative re-
search through a modified Delphi study to inform the 
pathway of SoC patients through the model.
 ► The model was calibrated and validated to accurate-
ly predict estimates of venous thromboembolism 
using published data from European cohort studies.
 ► Extensive sensitivity and scenario analyses were un-
dertaken to test the robustness of the results.
 ► Limitations are that our clinical and cost- 
effectiveness results are dependent on the accuracy 
of Pill Protect to predict the occurrence of venous 
thromboembolism events (which has been validated 
retrospectively but not yet prospectively or exter-
nally), and the hypothesis that all Swiss clinicians 
behave as assessed by our modified Delphi study.
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(thrombus) forms in one or more veins of the body. 
One particular form of venous thrombosis is called deep 
vein thrombosis (DVT). Here, the blood clot occurs in 
deep veins, typically of the legs. Such blood clots may 
travel through the bloodstream and lodge in lungs, 
where they can block blood flow, causing pulmonary 
embolism (PE). The term, venous thromboembolism 
(VTE), incorporates both conditions of DVT and PE.3 
The incidence of VTE increases with age from 1:100 000 
in children per year to 1:10 000 for individuals per year 
in the reproductive age, and finally to 1:1000 individ-
uals per year at the age of 50–60.4 All ages included, 
the disease occurs in 1–2 per 1000 individuals per year.5 
The association between dosage of EE in CHCs and VTE 
has been known since 1970,1 6 and recent studies show 
that VTE risk in CHC users is 3–18 times higher than 
for non- users according to the hormonal combination 
underlying the CHC.7
Genetic studies have identified many variations asso-
ciated with the development of VTE.8 Among them are 
variations in Factor V Leiden9 and Factor II G20210 (also 
known as prothrombin)10 or deficiencies in C and S 
proteins. In addition, VTE is a multifactorial disease influ-
enced by genetic factors but also by behavioural and envi-
ronmental factors such as smoking status and hormonal 
treatment. Several studies have developed algorithms to 
estimate thrombosis risk according to an individual’s clin-
ical and/or genetic profile,11 but few have estimated this 
for CHC users specifically. The field of personalised medi-
cine tailored to people’s genetic profiles by using specific 
algorithms is expected to expand in the next decades 
following recent initiation into Swiss clinical practice. 
Personalised approaches could be used to inform patients 
about their risk of VTE. For many first- time seekers of 
CHCs, genetic testing may flag up an increased VTE risk 
associated with a CHC prescription which exceeds the 
benefits and for which alternative contraceptive methods 
exist.
The Swiss Society of Gynaecology and Obstetrics 
(SSGO) guidelines and published recommendations12 
suggest that clinicians assess thrombosis risk in patients 
and only prescribe CHCs for those with low or no 
apparent thrombogenic risk. However, women often do 
not know their medical or family history and clinicians 
make qualitative judgements of when the combined risks 
of CHCs exceed the benefits.
The Pill Protect (PP) algorithm was developed and 
validated using published PILl Genetic Risk Monitoring 
and Cohort Lausanne cohorts.13 The algorithm quan-
tifies a CHC user’s VTE risk according to her genetic 
and behavioural characteristics. Retrospective valida-
tion results showed the algorithm successfully predicted 
thromboembolic events for oral contraceptive users (area 
under the receiver operator characteristic curve=0.71, 
95% CI 0.69 to 0.74). The algorithm underlies the PP 
genetic test currently reimbursed in Swiss clinical practice 
under certain conditions for health providers. Although 
several alternative tests evaluating clinical and genetic 
thrombosis risk exist, only PP assesses VTE risk related 
directly to CHC use.
Recent reviews of the literature have found scarcity of 
economic evaluations for screening genetic risk of VTE 
in first- time CHC users.14 15 Furthermore, most of the 
studies were based on short- term decision tree models, 
although a personalised microsimulation model may be 
a more appropriate specification.16 This is the first study 
to assess clinical, quality of life, cost outcomes and cost- 
effectiveness of the PP test when screening first- time 
seekers of CHCs at risk of VTE in comparison to the Swiss 
standard of care (SoC).
Methods
We developed an individual sampling model simulating 
VTE and other clinical events occurring over the life-
time of each woman based on her personal characteris-
tics (using Swiss and European prevalence data) and the 
contraceptive method recommended to her. One million 
women were simulated, and the model was populated 
with inputs derived from literature searches, national 
databases, local pharmacies and expert opinion from a 
modified Delphi study that we conducted. The model 
calculated annual outcomes for costs, VTEs, life years 
gained and quality- adjusted life years (QALYs) gained. 
Perspectives of cost assessed included a Swiss health system 
perspective considering direct medical costs irrespective 
of payer (base- case analysis), a health insurer perspective 
only considering reimbursement by insurers within the 
framework of the Swiss statutory health insurance (45% 
of inpatient services, 100% of drug treatment and PP 
test costs, 50% of laboratory fees and 0% of contracep-
tive interventions) and a societal perspective including all 
direct costs and productivity costs.
A lifetime time horizon (maximum of 85 years since 
model entry) was used for the model and considered 
appropriate as single and recurrent VTE events often 
occur in the longer term and may have long- term conse-
quences. However, the model does not take into consid-
eration that early detection of genetic risk for thrombosis 
might lead to prophylactic treatments later in life, except 
for the choice of contraception method. A discount rate 
of 3% for costs and outcomes was applied as is typical for 
Swiss economic evaluation.17
Population, intervention, comparator, outcomes and setting
Our analysis targeted Swiss women aged 15–29 years, as 
this was the age range of potential first- time users seeking 
CHCs elicited from the modified Delphi study described 
in the ‘strategy description’. The comparator was the 
Swiss SoC also described in strategy description, while 
the intervention incorporated the PP test into SoC. The 
setting was Switzerland, and the following outcomes were 
reported: VTEs, mortality, life years gained, QALYs, costs 
and cost per QALY gained.
strategy description
Schematic diagrams of the SoC and PP clinical pathways 
are illustrated in figure 1. For both SoC (figure 1A) and 
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Figure 1 (A) Clinical decision algorithm and resulting 
possible pathways, standard of care. (B) Clinical decision 
algorithm and resulting possible pathways, Pill Protect (PP); 
CHC, combined hormonal contraceptives; RR, relative risk.
Figure 2 Structure of Markov model.
PP (figure 1B), the first step for the clinician is to review 
the woman’s medical history and subsequently recom-
mend an alternative to CHCs (such as progestin- only pills, 
condoms, diaphragms or sponges), or prescribe a CHC. 
However, for the PP strategy, the first step also includes 
the completion of the PP test (refer to figure 1B), and if 
the test indicates high relative risk (RR) of VTE, a non- 
combined contraceptive is recommended. Otherwise, 
patients are automatically prescribed a CHC unless they 
have a positive family history of thrombosis in which case 
additional thrombophilia testing takes place and the 
result of this determines prescription of either a CHC 
or non- combined contraceptive. A threshold of 18 was 
established for a high RR of VTE; it was chosen because 
it is very close the highest naturally occurring risk in a 
woman’s lifetime (during the postpartum period).
We determined characteristics of SoC in practices of 
Swiss clinicians recommending CHCs, by undertaking a 
modified Delphi study between 2017 and 2018. We asked 
questions to clinicians related to how general practice for 
recommending CHCs in Switzerland is carried out. Nine-
teen gynaecologists completed the first round, six the 
second round (97% agreement) and three participated 
in a final round used to clarify a few questions where 
second round consensus was not reached. The results of 
the Delphi study indicated that clinicians’ prescription 
processes in Switzerland are broadly aligned with SSGO 
recommendations12 (refer to online supplementary 
appendix table A1). Clinicians are cautious in prescribing 
CHCs to women with apparently high VTE risk, and often 
seek further biochemical (ie, Protein C, S, lupus anti-
coagulants, etc.) and genetic tests (ie, Factors II and V) 
if positive family history of VTE is present. In addition, 
they do not prescribe CHCs to women with a confirmed 
genetic risk (ie, Factor II or V Leiden), and at times avoid 
CHC prescription in the presence of multiple clinical risk 
factors (ie, body mass index (BMI), smoking, age), even 
when genetic testing has confirmed the absence of Factor 
II G20210A and Factor V Leiden mutations which are 
known to be contributing to thrombosis risk.
Modelling
We developed a microsimulation model in StataMP V.15 
(College Station, TX, USA). Within the model, events 
occur at an individual level. The simulation of 1 million 
women seeking prescription of contraception for the first 
time was generated based on characteristics of age, BMI,18 
smoking status,19 family history13 and nine genetic factors.
The first step in the model simulates each patient 
through a clinical decision pathway, determined by the 
strategy (PP or SoC), to establish whether or not a CHC is 
prescribed based on the patient’s baseline characteristics. 
Once the contraceptive intervention is determined for 
each individual (CHC or non- combined contraceptive), 
each woman enters the Markov part of the model for her 
lifetime. This is done separately for the SoC and PP strate-
gies. The model contains five main health states: no VTE, 
first VTE, second VTE, post- VTE and death (figure 2). 
Through this state- transition modelling, costs and utili-
ties associated with each health state are calculated and 
accrued over the lifetime. Details on the different health 
states are provided next.
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Each woman begins the model without previous VTE 
event (‘no VTE’) but is at risk of death or having a first 
VTE (‘first VTE’). If a VTE occurs, the model determines 
whether it is DVT only or also PE. A patient who survives 
the VTE then remains in the post- VTE health state for her 
remaining life (until ‘death’) or until another VTE event 
occurs (‘second VTE event’). Options for transitions after 
second VTE mirror those after first VTE, however the 
event probabilities may differ.
The post- VTE health state comprises women after one 
or two VTE events. Here, additional morbidity associ-
ated with living after VTE is incorporated (table 1). It is 
assumed CHC use is stopped after a VTE, and contracep-
tion switched to a non- combined variety. Costs of contra-
ception continue to incur for the period each woman is 
estimated to use contraception, determined at baseline in 
the model. The model is run for each woman up until the 
point she reaches the ‘death’ state.
Modelling assumptions
Key modelling assumptions include: the estimates derived 
from PP algorithm accurately predict relative VTE risk 
of women with different risk factors. The data obtained 
from the modified Delphi panel accurately represent 
actual clinical practice related to contraceptives prescrip-
tion in Switzerland. Also, we assumed the PP algorithm in 
combination with appropriate calibration allowed appro-
priate modelling of real- life occurrence and distribution 
of VTE events. We also assumed that risks from CHCs 
were only present while women take CHCs (ie, no spill-
over effects) and additional surgery and life events that 
possibly increase VTE risk did not occur during one’s life-
time. We limited the number of recurring VTE events to 
‘two’ at most, and due to lack of evidence, did not incor-
porate further risk reduction of VTE for those given anti-
coagulant prophylaxis (ACP) after VTE.
Validation and calibration
Several modelling calibration and validation exercises 
were undertaken. Primarily, the model was first designed 
in Microsoft Excel 2016 and then duplicated in StataMP 
V.15. Both models produced alike results demonstrating 
internal validity. In addition, parameters relating to abso-
lute incidence of VTE were calibrated against a Danish 
cohort study for women aged 15–50 years20 and a Swedish 
cohort study for women aged over 50.21 In order that 
accurate results in comparison to the cohort studies 
were produced, we adjusted the VTE incidence param-
eters estimated from the risk algorithm underlying the 
PP test,13 by an age- related calibration factor. We tested 
several age- related calibration factors and applied the 
factor providing results closest to the cohort studies. The 
weighted- average incidence of VTE in CHC non- users 
(ages 15–29) was 1.7 per 10 000 women years based on 
the 8- year Danish cohort study.20 Our model predicted 
a similar VTE incidence in the same age population, 
of 2.1 per 10 000 women years when the model was run 
for a duration of 8 years. Our slightly higher result was 
probably driven by our age distribution, as the median 
entry age into our model was 21 years; hence, the inci-
dence estimate is similar to those of the same age in the 
Danish cohort study (ie, ages 20–24; VTE incidence 2.1. 
per 10 000 women years). The median life expectancy 
simulated by the model was 87 years, which indicates 
validity as it is close to actual life expectancy of Swiss 
women (85 years).
Model input parameters
Clinical efficacy, event and population characteristics
Table 1 summarises population, clinical efficacy and 
event parameters used for the analysis. Parameters 
relating to population characteristics, BMI and expected 
duration of CHC use according to age are detailed in 
online supplementary appendix table A2–A4. The prob-
ability that a woman has a first VTE event was calculated 
using the PP algorithm derived from a study by McDaid 
et al13 (for additional calibration to real world data, see 
above). One of the algorithm components is the RR of 
having a VTE related to a CHC according to its gener-
ation or formulation (ie, second, third, fourth, cypro-
terone acetate, etc.). This RR of VTE for CHC users 
compared with non- users was derived from pooled esti-
mates of cohort studies reported by Martinez et al.22 RR 
of VTE for the progestin- only pill and non- hormonal 
contraception was estimated to be 1.03 (95% CI 0.76 to 
1.39) and 1, respectively.
The proportion of VTE events that were DVT and PE 
were 41.0% and 59.0%, respectively, derived from a USA 
population study.23 A Danish database was used to deter-
mine that onset of DVT resulted in 1.5% cardiovascular 
events (myocardial infarction (MI) or stroke) and onset 
of PE resulted in 1.7% cardiovascular events in the first 
year.24 Probability of death related to PE and DVT was 
derived from Italian hospital records.25 To understand 
recurrence of VTE, a study by Laczkovics et al in 2007 was 
used.26 Mortality for recurrent VTE was assumed to be the 
same as for first VTE.
Underlying probability of death from general causes is 
based on Swiss Federal Statistical Office (SFSO) lifetables.
Health-related quality of life (HRQoL)
Table 1 summarises HRQoL values for the model. Utility 
(preference- based HRQoL) in the female Swiss popu-
lation is based on a Swiss- specific valuation algorithm.27 
Using this algorithm, the microsimulation model calcu-
lates age- related utility on an annual basis, and when a 
VTE event occurs, or a woman remains in post- VTE, the 
weighted disutility of PE and DVT is applied.
Disutility values after DVT28 and PE28 were derived from 
Norwegian data. This disutility was applied long term in 
the post- VTE state as the studies that the values were taken 
from estimated disutility resulting from DVT/PE for at 
least 10 years following the event. Disutilities for stroke 
and MI events were derived from an external study.29
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Table 1 Key model inputs
Inputs Mean estimate (95% CI) Source
Clinical efficacy and event inputs
RR of contraceptives
  Second generation: levonorgestrel 3.48 (2.26 to 5.09) Martinez et al 201222
  Third generation : gestodene, desogestrel 5.65 (3.67 to 8.28)
  Fourth generation: drospirenone, dienogestrel 5.78 (3.05 to 10.61)
  Cyproterone acetate 5.74 (3.74 to 8.39)
  Other (ie, Qlaira) 3.48 (2.26 to 5.09)
  Progestogen only: desogestrel 1.03 (0.76 to 1.39) Mantha et al 201243
  Non- combined: that is, of condoms, IUD, and so on 1 Assumption
Proportion of CHCs
  Second generation: levonorgestrel 47.7% (45% to 50.4%) Modified Delphi study
  Third generation: gestodene, desogestrel 27.0% (24.6% to 29.4%)
  Fourth generation: drospirenone, dienogestrel 17.5% (15.4% to 19.5%)
  Cyproterone acetate 7.1% (6.1% to 8.1%)
  Other (estradiol valerate/dienogest, etonogestrel, 
chlormadinone acetate)
0.8% (0.5% to 1.1%)
Proportion of non- CHCs
  Non- CHCs: desogestrel 42.3% (39.4 to 45.2) Modified Delphi study
  Non- CHCs: that is, condoms, contraceptive sponge, 
and so on
57.7% (49.1 to 66.3)
VTE- related events
  Proportion of VTE that is DVT alone 41% Silverstein et al, 199823
  Proportion of VTE that is DVT and PE 59%
Probability
  DVT leads to MI or stroke 0.015 Sørensen et al, 200724
  PE leads to MI or stroke 0.017
  Mortality for PE 0.045 (0.031 to 0.065) Compagni et al, 201325
  Mortality for DVT 0.007 (0.0033 to 0.0128)
  Probability of recurrent VTE 0.0429 Laczkovics et al, 200726
Utility inputs
Constant 0.84822 Perneger et al, 201027
  Age coefficient 0.00208
  Age coefficient2 0.00002
  Gender coefficient*NOTE=1, since female 0.02090
  VTE PE disutility −0.09 Tavoly et al, 201628
  VTE DVT disutility −0.08 Utne et al, 201628
  Disutility stroke −0.2547 Sullivan et al 201129
  Disutility MI (acute) −0.1690
  Death 0.00 Assumption
Cost inputs
Consultation costs
  Consultation with clinician for CHC: first visit CHF 91 TARMED Tarifbrowser 1.08 
(22.001),32
Modified Delphi study
  Consultation with clinician for CHC: second visit CHF 91 TARMED Tarifbrowser 1.08 
(22.001)32  Third visit (if labs required) CHF 91
Continued
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Inputs Mean estimate (95% CI) Source
  PP test CHF 270 Gene Predictis (oral 
communication, 21 March 2017)
Laboratory testing
  Laboratory testing for FV Leiden/FII) (including 
administrative and extraction fees)
CHF 616 (553 to 679) Viollier Switzerland,44
SFOPH, Analysenliste (AL) 2021, 
4700,44
Modified Delphi study
  Laboratory testing for Protein C, S and Lupus 
anticoagulant only (including administrative fees)
CHF 185 (241 to 252) Viollier Switzerland,44
SFOPH, AL, SFOPH, 4700, 
SFOPH,45
Modified Delphi study
  Extraction cost for DNA testing (FV Leiden/FII) CHF 61 SFOPH, AL 202145
  Administrative costs for any laboratory testing (added 
tax)
CHF 24 SFOPH, AL 470045
Hospitalisation costs, VTE
  DVT CHF 6813 (6501 to 7194) SFSO,18 DRG F6346
  PE CHF 8722 (8499 to 9033) SFSO,18 DRG E6446
  Cardiovascular events related to VTE
  MI CHF 9141 (8974 to 9401) SFSO,18 DRGs F41, F6046
  Stroke CHF 13 940 (13 262 to 13 744) SFSO,18 DRGs B04B, B39, B7046
Haematologists consultations and visits
  Cost per one outpatient visit
  (patients require two visits in the first year to manage 
VTE)
CHF 132 TARMED Tarifbrowser 1.08, 
22.00232
  Anticoagulant prophylaxis
  (3 months)
CHF 238 SFOPH, Spezialitaetenliste32
  CHC generation: progestin contained Annual costs
  Second generation: levonorgestrel CHF 143 (128 to 157) TopPharm Pharmacies (toppharm 
Apotheke)  Third generation : gestodene, desogestrel CHF 169 (152 to 186)
  Fourth generation: drospirenone, dienogestrel CHF 226 (20 to 249)
  Cyproterone acetate CHF 170 (153 to 187)
  Other CHF 302 (263 to 340)
Non- combined contraceptives
  Progestogen only: desogestrel CHF 228 (205 to 251) TopPharm Pharmacies (toppharm 
Apotheke)
  Non- combined alternatives CHF 177 (159 to 195) Apotheke HERSBERGER BASEL
Indirect costs
  Productivity loss per disability claim DVT (short term) CHF 4286 (CHF 2857 to 9183) SFSO data and expert opinion
  Productivity loss per disability claim PE (short term) CHF 6122 (CHF 2857 to 9183) SFSO data and expert opinion
CHCs, combined hormonal contraceptives; CHF, Swiss Francs;DRG, diagnosis- related group; DVT, deep venous thrombosis; FII, Factor II; FV, 
Factor V;IUD, intrauterine device; MI, myocardial infarction; PE, pulmonary embolism; PP, Pill Protect;RR, relative risk; SFOPH, Swiss Faculty 
of Public Health; SFSO, Swiss Federal Statistical Office; VTE, venous thromboembolism event.
Table 1 Continued
Health resource use and direct costs
Table 1 details cost and resource use values for the 
model. We selected unit costs in Swiss francs (CHF) 
and 2016 prices. Costs derived from older sources were 
inflated to 2016 values using the Swiss Consumer Price 
Index provided by the SFSO.30 Direct costs related to 
recommending contraception in Switzerland included 
gynaecologist visits and, where applicable, the PP test, 
thrombophilia tests and further biochemical tests for 
women with low PP RR scores but positive family history 
of VTE.
Hospitalisation costs related to a VTE event, stroke or 
MI were derived from the Swiss diagnosis- related group 
(DRG) reimbursement database.31 Where more than one 
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DRG was relevant, the weighted average was calculated. 
Unit costs for haematologist visits for women with a VTE 
were derived from TARMED,32 and we assumed visit dura-
tion of 30 min. Unit costs for drugs with relevant Anatom-
ical Therapeutic Chemical Classification System codes 
were obtained from the Swiss Federal Office of Public 
Health Specialty List.33
Market share data and costs of CHCs were provided by 
TopPharm Pharmacies in Basel, Switzerland.34 The annual 
cost for non- combined contraceptives was taken from a 
weighted average of the costs of condoms, diaphragms, 
contraceptive sponges and contraceptive pills that only 
include desogestrel from a Swiss pharmacy (personal 
communication, Prof. Hersberger).
Indirect costs related to productivity losses based on 
SFSO data35–37 and expert opinion were included in the 
societal perspective. Additional details regarding these 
calculations are provided in the online supplementary 
appendix.
one-way sensitivity analysis
We varied all key model input parameters (refer to 
table 1) individually using the 95% CI when available or 
otherwise ±25% of the base- case value.
Probabilistic sensitivity analysis (PsA)
In accordance with Consolidated Health Economic Eval-
uation Reporting Standards guidelines,38 we included 
analysis of joint parameter uncertainty through a PSA by 
running the model using parameter distributions instead 
of mean values, to generate 1000 simulations. The inputs 
in the PP algorithm calculating the VTE and the PP RR 
score, and characteristics related to the population of 
1 million women remained fixed, except for the mean 
estimate of protein C/S prevalence which was assigned a 
beta distribution. Proportions derived from our modified 
Delphi study were also assigned beta distributions. Log 
normal distributions were assigned to RR parameters with 
the SE of the ln(RR) calculated from the 95% CI derived 
from the original studies. For parameters with no avail-
able 95% CI, the SE was assumed to be 10% of the mean 
estimate. Beta distributions were assigned to transition 
probabilities, and gamma distributions to cost inputs and 
utility decrements.
scenario analyses
We investigated 12 scenarios varying key model parame-
ters by running analyses where:
1. Only high- risk individuals, based on the assessment 
by SGGO questionnaire (having a family history with 
two or more clinical risk factors), proceeded through 
the PP algorithm within the PP strategy.
2. Only low- risk individuals, based on the assessment by 
SGGO questionnaire, proceeded through the PP al-
gorithm within the PP strategy.
3. The age of first- time users varied (15–49 years old).
4. The proportion of clinicians who review a woman’s 
medical history was varied. In scenario 4a, it was 
assumed that 100% of clinicians considered medical 
history in the SoC and PP strategies, while scenario 
4b assumed 100% of clinicians, in the PP strategy 
only, considered medical history.
5. We assumed that if more than one clinical risk factor 
was present, all clinicians did not recommend CHCs.
6. Discount rates varied to 2% and to 5%.
7. Shortened time horizons of 15, 30 and 50 years were 
evaluated.
8. The PP RR threshold of 18 in the base case varied 
from 5 to 40.
9. The clinical decision algorithm of ‘SoC’ was adjust-
ed. For 9a, we assumed that no clinical decision al-
gorithm was applied in the SoC strategy and 100% 
of SoC women received CHCs, for 9b assumed only 
second generation CHCs were prescribed if a CHC 
was recommended; and for 9 c assumed no clinical 
decision algorithm was applied in SoC and 100% of 
SoC women received a progesterone- only pill.
10. Variations in the market share were applied. For 
10a, we based the distribution of CHCs prescribed 
on Swiss market share data (31% second genera-
tion, 38% third generation, 22% fourth generation, 
9% cyproterone acetate CHCs). For 10b, 100% of 
SoC women were given contraception according to 
a random sampling distribution of Swiss market pro-
portions (17% given non- combined contraception, 
26% second generation CHC, 32% third generation, 
19% fourth generation, 7.5% cyproterone acetate 
CHC).
11. We assessed the impact of using the PP test instead of 
a Factor II or a Factor V test.
12. The CHC duration in 15–19 years old women was as-
sumed to be the maximum possible duration (until 
50 years old or occurrence of a VTE).
Patient and public involvement (PPI)
There was no PPI for this study.
results
Base- case results analysis showed the PP strategy is associ-
ated with 21 fewer VTE- related deaths and 669 fewer first 
VTEs (table 2) for a population of 1 million women over 
their lifetime horizon. The PP strategy was also associated 
with higher costs relative to SoC mostly attributable to 
the addition of the PP test itself, and more CHC prescrip-
tions (table 3). These higher costs were to a small part 
offset by reductions in unneeded thrombophilia labora-
tory testing, VTE- related hospitalisations and treatments, 
and prescriptions of non- combined contraceptives which 
cost more than CHCs in Switzerland. For the PP strategy 
in comparison with the SoC strategy, base- case cost- 
effectiveness results indicated slightly higher discounted 
health system costs of CHF 231 per woman and a gain 
of approximately 0.003 QALYs per woman, generating 
an incremental cost- effectiveness ratio (ICER) of CHF 
76 610 per QALY gained (table 4). When the PP strategy 
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Table 2 Results: clinical outcomes without discounting, 
base- case scenario
SoC PP Incremental*
Average LYGs 64.038 64.041 0.002
Average age at 
death
84.410 84.412 0.002
Persons with 
CHCs prescribed
733 361 763 705 30 344
Number of first 
VTEs†
108 026 107 357 −669
VTE- related deaths 3418 3397 −21
*Incremental calculations based on Pill Protect (PP) standard of 
care (SoC).
†This was estimated over a lifetime (since model entry) and not 
only during the lifespan when combined hormonal contraceptives 
(CHCs) are taken.
LYG, life years gained; VTE, venous thromboembolism event.
Table 3 Results for costs per women (CHF), health system perspective
Undiscounted Discounted
SoC PP Incremental* SoC PP Incremental*
PP 0 270 270 0 270 270
Consultation 182 182 0 182 182 0
Laboratory testing 34 11 −22 34 11 −22
CHCs 1314 1372 57 1085 1132 47
Non- CHCs 579 511 −68 476 421 −55
VTE inpatient 906 900 −6 243 235 −8
VTE treatment (ACP) 26.70 26.53 −0.17 7.16 6.93 −0.23
VTE (MI/stroke) 20.97 20.83 −0.14 5.63 5.44 −0.19
Total costs 3062.67 3293.36 230.69 2032.79 2263.37 231.58
*Incremental calculations based on Pill Protect (PP) standard of care (SoC).
ACP, anticoagulant prophylaxis; CHCs, combined hormonal contraceptives; MI, myocardial infarction; VTE, venous thromboembolism event.
was assessed from the societal and health insurer perspec-
tives, ICERs of CHF 75 229 and 84 624 per QALY gained 
were generated, respectively.
The key input parameters in the model were varied 
individually in one- way sensitivity analyses (online supple-
mentary appendix figure A1). None of these variations 
resulted in an ICER over CHF 100 000 per QALY. Assess-
ment of the parameters with the biggest impact on cost 
effectiveness show that reducing the proportion of clini-
cians who conduct a medical history assessment before 
prescribing a CHC had the biggest impact (online supple-
mentary appendix figure A1).
We conducted 12 scenario analyses (table 5). Scenario 
1 indicated that PP was cost effective when targeting only 
high- risk individuals. On the other hand, PP generated 
an ICER of CHF 53 708 per QALY gained where high- risk 
women (with two combined clinical risk factors and/or 
positive family history of VTE) received a non- combined 
contraceptive in any case, and women with no apparent 
risk were assessed using PP (scenario 2b).
We tested scenarios that were less likely to occur. In 
scenario 10b, PP was associated with an ICER of CHF 31 
138 per QALY gained. Here, clinicians were assumed to 
prescribe CHCs according to the market share in Swit-
zerland (without considering medical history). Under 
scenario 12, where women who were first prescribed 
CHCs during their adolescent years remained on CHCs 
until 50 years old (unless VTE occurs sooner), PP was 
associated with an ICER of CHF 28 911 per QALY gained. 
Under scenario 8 where the PP RR threshold which deter-
mines whether the patient undergoes further thrombo-
philia testing or not was reduced, ICERs close to CHF 50 
000 per QALY gained were produced.
In the PSA, we found the probability of PP being cost 
effective assuming a CHF 100 000 per QALY gained 
threshold exceeded 99% (figures 3 and 4).
dIsCussIon
We developed an individual sampling model to assess the 
cost effectiveness of a PP strategy where the PP test is used 
to inform the prescription of CHCs, with the purpose of 
reducing overall risks of contraceptive users experiencing 
VTEs. The PP strategy (PP test combined with SoC) was 
compared with SoC alone in terms of costs and QALYs 
accruing over the lifetime of Swiss women aged 15–29 
years who are potential first- time users seeking CHCs. 
The economic evaluation was conducted from the Swiss 
health system, health insurer and societal perspectives. In 
the base case, PP generated ICERs of CHF 76 610, 75 229 
and 84 624 per QALY gained for the health system, soci-
etal and health insurer perspectives, respectively. The 
results were quite robust across a wide range of sensitivity 
and scenario analyses. Considering a cost- effectiveness 
threshold in Switzerland of CHF 100 000 per QALY 
(tentatively assumed in other Swiss analyses), and if our 
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Table 4 Results, cost effectiveness, base- case scenario
Undiscounted Discounted
SoC PP Incremental*
ICER
(CHF per 
QALY) SoC PP Incremental*
ICER (CHF 
per QALY)
Average QALYs per woman 51.803 51.810 0.007 23.901 23.904 0.003
Average costs per woman 
(CHF)
Health system 3063 3294 231 32 642 2033 2264 231 76 610
Societal 3471 3699 228 32 169 2148 2374 227 75 229
Health insurer 543 799 256 36 147 218 473 255 84 624
*Incremental calculations based on Pill Protect (PP) standard of care (SoC).
CHF, Swiss francs; ICER, incremental cost- effectiveness ratio; QALY, quality- adjusted life year.
main assumptions hold true, the PP strategy may be cost 
effective for the studied population.
Our results show that many apparently low- risk indi-
viduals are in fact at substantial risk, with young women 
especially affected. The latter is further supported by real- 
world data that show that substantial number of DVTs 
related to CHC occur every year in Switzerland39 despite 
the clinical screening indicated by the modified Delphi 
study. Furthermore, other publications already indicated 
that the limited number of genetic tests included in the 
standard trombophilia testing (Factor II G20210A variant 
and Factor V Leiden), as well as the clinical information 
assessed, are insufficient to reliably estimate risk of DVT 
(de Haan H.G. et al40; Suchon P, et al.41
Primarily, we found that the PP test may present value 
for women ages 15–29 in general, and for individuals 
perceived as ‘low risk’ with no obvious non- genetic risk 
factors. Based on the model presented in here (notably 
scenario 2b), it appears that from the economic and clin-
ical point of view, an effective strategy would be to keep 
first screening all women through the SGGO question-
naire and then use the PP test to further assess the risk for 
women that initially appeared to be at ‘low risk’. According 
to this approach, women that appear at high risk with the 
questionnaire would be prescribed a non- CHC contracep-
tion immediately, while women that appear at ‘low risk’ 
would then undergo PP testing and potentially additional 
laboratory testing for Protein S, lupus antigens, and so 
on (eg, when there is a presence of positive family history 
and PP results indicate low genetic risk) and would finally 
be prescribed CHC or non- CHC based on the laboratory 
results. Second, our scenario analyses also highlighted 
that the screening of younger women maintains the best 
values (scenario 3a and b), especially if young women 
continue to take prescribed CHCs for the duration of 
their childbearing years (scenario 12).
Another strength of this analysis is that it has incor-
porated current prescribing patterns in Switzerland by 
directly eliciting behavioural patterns through a modi-
fied Delphi study. This enabled us to model SoC pathways 
for recommending CHCs related to age, which gener-
ally aligned with SSGO guidelines12 (which recommend 
undertaking precautionary measures and additional 
assessments for patients presenting VTE risk). However, 
although SSGO guidelines recommend that ‘low’-risk 
CHCs (second generation) are prescribed, the Delphi 
experts and market share data indicated that further 
generations are regularly prescribed instead. The addi-
tional benefits associated with further generations may 
explain this lack of adherence to the SSGO guidelines. 
Nonetheless, the results demonstrate that the role of clini-
cians and adherence to guidelines do impact cost effective-
ness (scenario 4) and hence understanding prescribing 
patterns and patient preferences for CHCs will remain to 
be key in maintaining cost- effective approaches from the 
Swiss perspective.
Study limitations include assuming PP realistically 
predicts VTE events and adequately reflects proportional 
risks from genetic and clinical risk factors, and assuming 
the SoC pathway in the model realistically represents real 
clinical practice in Switzerland. The PP algorithm has 
been developed and validated retrospectively in a cohort 
comprising about 800 women who developed VTE while 
using CHCs and a similar number of controls who were also 
CHC users, using state- of- the- art split- sample methods.13 
While it has been shown to perform better than other 
published models and is the first model specific to CHC 
use, external validation has not yet occurred. Modelling 
also assumed that BMI remained constant throughout 
the lifetime and that laboratory testing costs were covered 
by health insurance in 50% of cases. Also, few clinicians 
participated in the second and third rounds of the Delphi 
study. Finally, it was beyond the model scope to capture 
certain risk factors for VTE including pregnancies, 
surgeries and more than two occurences of VTE in one’s 
lifetime. Nevertheless, it would be interesting to assess 
the potential benefits that could appear if all women with 
high genetic risk of thrombosis would be identified early 
enough and preventatively treated during pregnancy and 
post partum.
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Figure 3 Cost- effectiveness planes for the health system, 
health insurer and societal perspectives; CHF, Swiss francs; 
QALYs, quality- adjusted life years.
Figure 4 Cost- effectiveness acceptability curves; CHF, 
Swiss francs; QALYs, quality- adjusted life years.
Our literature review found that PP is currently the only 
algorithm available for screening for VTE risk related to 
CHCs, although other algorithms potentially marketable 
as products for future practice exist, such as ThromboIn-
Code.42 Although this algorithm is not yet available in 
Switzerland and not specifically indicated for use in CHC 
prescribing, it potentially may be used in this way and 
considered a competitive alternative test. However, the 
PP test assesses more genetic variants linked to VTE risk 
in the context of CHC use than ThromboInCode. Never-
theless, future comparison of ThromboInCode with PP 
might be informative.
Overall, this study has indicated an opportunity for PP 
to provide accurate diagnosis and cost- effective benefits 
when used during the first recommendation of contra-
ceptives for young women in Switzerland.
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